Literature DB >> 20935690

Change in outflow pathway of porcine eyes in vitro by nonpenetrating filtering surgery.

Wen Xu1, Ke Yao, Wei Wu, Zhaochun Li, Panpan Ye.   

Abstract

OBJECTIVE: To study the change in different outflow pathways of porcine eyes in vitro by nonpenetrating filtering surgery.
DESIGN: Experimental study. PARTICIPANTS: Sixty-four enucleated porcine eyes were studied.
METHODS: Deep sclerectomy was performed on isolated porcine eyes (Group 1A), then the superficial scleral flap was watertight sealed (Group 1B), and finally the oracles and the exterior wall of the Schlemm canal were watertight sealed (Group 1C). In another series of experiments, deep sclerectomy was performed with the scleral lake volume of 4 mm × 4 mm × 0.5 mm (Group 2A), 4 mm × 2 mm × 0.5 mm (Group 2B), and 4 mm × 1 mm × 0.5 mm (Group 2C), respectively; then the superficial scleral flap was watertight sealed. The control eye (Groups 1D and 2D) underwent creation and watertight sealing of a superficial scleral flap. Intraocular pressure (IOP) and outflow facility were determined preoperatively and postoperatively.
RESULTS: Compared with the preoperative value, IOP was decreased and outflow facility was increased in Groups 1A, 1B, and 1C (p < 0.05). In deep sclerectomy, the outflow facility was decreased by more than 0.18 µL/min/mm Hg after the conjunctival pathway was blocked. After the oracles and external wall of the Schlemm canal were blocked, the outflow facility decreased further by more than 0.09 µL/min/mm Hg but was still 0.06 µL/min/mm Hg higher than before surgery. There was a positive linear correlation between the deep sclerectomy volume and the ratio of IOP decrease or outflow facility increase postoperatively.
CONCLUSIONS: Deep sclerectomy can increase the outflow of porcine eyes in vitro. The major factors maintaining the postoperative outflow increase include the subconjunctival pathway, the functional deep scleral lake, and the opening of the Schlemm canal.

Entities:  

Mesh:

Year:  2010        PMID: 20935690     DOI: 10.3129/i10-056

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  7 in total

1.  Five-year results of non-penetrating deep sclerectomy with demineralized cancellous bone xenogenically derived collagen glaucoma implant.

Authors:  Natalia S Anisimova; Lisa B Arbisser; Sergey I Anisimov; Lusine L Arutyunyan; Natalya F Shilova; Gilyana Bashaeva; Roman V Kirtaev; Svetlana Yu Anisimova
Journal:  Int Ophthalmol       Date:  2021-03-03       Impact factor: 2.031

2.  Deep sclerectomy with mitomycin C in eyes with failed glaucoma surgery and pseudophakia.

Authors:  N Anand; D Wechsler
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

3.  Outcomes of combined phacoemulsification and deep sclerectomy: a 10-year UK single-centre study.

Authors:  K Mercieca; B Shevade; N Anand
Journal:  Eye (Lond)       Date:  2015-09-04       Impact factor: 3.775

Review 4.  A New Ultrasound Biomicroscopic Sign seen after Deep Sclerectomy (Dolphin Head Sign).

Authors:  Ahmed M Abdelrahman; Hala M El Cheweikh; Dina Ms El-Fayoumi; Riham Shm Allam
Journal:  J Curr Glaucoma Pract       Date:  2016-08-05

5.  Rapid learning curve assessment in an ex vivo training system for microincisional glaucoma surgery.

Authors:  Yalong Dang; Susannah Waxman; Chao Wang; Hardik A Parikh; Igor I Bussel; Ralitsa T Loewen; Xiaobo Xia; Kira L Lathrop; Richard A Bilonick; Nils A Loewen
Journal:  Sci Rep       Date:  2017-05-09       Impact factor: 4.379

6.  Long-term results of deep sclerectomy with small collagen implant in Korean.

Authors:  Seungsoo Rho; Sung Yong Kang; Samin Hong; Gong Je Seong; Jong Jin Jung; Chan Yun Kim
Journal:  Korean J Ophthalmol       Date:  2013-01-09

7.  Perilimbal sclera mechanical properties: Impact on intraocular pressure in porcine eyes.

Authors:  Xiaofei Man; Elizabeth Arroyo; Martha Dunbar; David M Reed; Neil Shah; Larry Kagemann; Wonsuk Kim; Sayoko E Moroi; Alan Argento
Journal:  PLoS One       Date:  2018-05-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.